Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the cholesterol and recurrent events (CARE) trial

Annals of Internal Medicine

Volumn 129, Issue 9, 1998, Pages 681-689

  Lewis, Sandra J ^a   Moye, Lemuel A ^b   Sacks, Frank M ^c   Johnstone, David E ^d   Timmis, Gerald ^e   Mitchell, Jayne ^f   Limacher, Marian ^g   Kell, Sherron ^h   Glasser, Stephen P ⁱ   Grant, Jane ^j   Davis, Barry R ^b   Pfeffer, Marc A ^k   Braunwald, Eugene ^k  

^a LEGACY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f Box 100 277 ^*  (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELDERLY CARE; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 14444271787     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-9-199811010-00002     Document Type: Article

References (49)

1. National Center for Health Statistics: advance report of final mortality statistics, 1982. Monthly Vital Statistics Report. No. 9, supp. DHHS pub. no. (PHS) 85-1120. Washington, DC: U.S. Public Health Service; 20 December 1984.
2. Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital Health Stat. 1991;1-236.
3. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268:1417-22.
4. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996; 124:292-8.
5. Ellerbeck EF, Jencks SF, Radford MJ, Kresowlk TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-year pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-14.
6. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-21.
7. Paul SD, O'Gara PT, Mahjoub ZA, DiSalvo TG, O'Donnell CJ. Newell JB, et al. Geriatric patients with acute myocardial infarction: cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. Am Heart J. 1996;131:710-5.
8. Devlin W, Cragg D, Jacks M, Friedman H, O'Neill W, Grines C. Comparison of outcome in patients with acute myocardial infarction aged >75 years with that in younger patients. Am J Cardiol. 1995;75:573-6.
9. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med. 1996;124:283-91.
10. McLaughlin TJ, Soumerai SB. Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
11. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-14.
12. Krumholz HM, Forman DE, Kuntz RE, Baim DS, Wei JY. Coronary revascularization after myocardial infarction in the very elderly: outcomes and long-term follow-up. Ann Intern Med. 1993;119:1084-90.
13. Pashos CL, Newhouse JP, McNeil BJ. Temporal changes in the care and outcomes of elderly patients with acute myocardial infarction, 1987 through 1990. JAMA. 1993;270:1832-6.
14. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA. 1994;272:859-66.
15. Rich MW. Therapy for acute myocardial infarction. Clin Geriatr Med. 1996; 12:141-68.
16. Aronow WS, Herzig AH, Etienne F, D'Alba P, Ronquillo J. 41-month follow-up of risk factors correlated with new coronary events in 708 elderly patients. J Am Geriatr Soc. 1989;37:501-6.
17. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med. 1990;113:916-20.
18. Benfante R, Reed D. Is elevated serum cholesterol a risk factor for coronary heart disease in the elderly? JAMA. 1990;263:393-6.
19. Barrett-Connor E, Suarez L, Khaw K, Criqui MH, Wingard DL. Ischemic heart disease risk factors after age 50. J Chronic Dis. 1984;37:903-8.
20. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335-40.
21. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-80.
22. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med. 1993;153:1065-73.
23. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2:161-76.
24. Hazzard WR. Dyslipoproteinemia in the elderly. Should it be treated? Clin Geriatr Med. 1992;8:89-102.
25. Bearden DM, Allman RM. Should hyperlipidemia in the elderly be treated? Drug Therapeutics. 1992;22:1-53.
26. Gordon DJ, Rifkind BM. Treating high blood cholesterol in the older patient. Am J Cardiol. 1989;63:48H-52H.
27. Tikkanen MJ. Hypercholesterolaemia in the elderly: is drug treatment justified? Eur Heart J. 1988;9(Suppl D):79-82.
28. Hulley SB, Newman TB. Cholesterol in the elderly. Is it important? [Editorial] JAMA. 1994;272:1372-4.
29. Bilheimer DW. Clinical considerations regarding treatment of hypercholesterolemia in the elderly. Atherosclerosis. 1991;91:535-57.
30. Leaf DA. Lipid disorders: applying new guidelines to your older patients. Geriatrics. 1994;49:35-41.
31. Hulley SB, Walsh JM, Newman TB. Health policy on blood cholesterol. Time to change directions [Editorial]. Circulation. 1992;86:1026-9.
32. Corti MC, Guralnik JM, Salive ME, Harris T. Ferrucci L. Glynn RJ, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126:753-60.
33. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23.
34. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-5.
35. Buring JE, O'Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB, et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation. 1992;85:22-9.
36. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men and women with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
37. Rubins HB, Robins SJ, Collins C, Iranmanesh A, Wilt TJ, Mann D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995; 75:1196-201.
38. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-9.
39. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436-46.
40. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: Iowa State Univ Pr; 1980:64-8, 194-214.
41. Lee ET. Statistical Methods for Survival Data Analysis. 2d ed. New York: Wiley; 1992:250-63.
42. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand, 1988;223:405-18.
43. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in saturated fat in preventing complications of atherosclerosis. Circulation. 1969;39 and 40(Suppl II):II1-II63.
44. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74.
45. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
46. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
47. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9(4 pt 1):342-60.
48. Shepherd J, Blauw G, Murphy M. The PROSPER design: a prospective study of pravastatin in the elderly at risk. In: Paoletti R, ed. Drugs Affecting Lipid Metabolism. Milan: Fondazione Giovanni Lorenzini; 1998:108.
49. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995;346:1647-53.